Gender-Affirming Hormone Therapy for Breast Cancer in Transgender and Gender-Diverse Individuals: Unresolved and Unaddressed Issues

Overview

Journal Mayo Clin Proc

Specialty General Medicine

Date 2024 Dec 6

PMID 39641711

Authors

Sanjna Rajput

Aminah Jatoi

Caroline Davidge-Pitts

Elizabeth J Cathcart-Rake

Affiliations

Soon will be listed here.

References

Cortina C . Inclusion and Reporting of Transgender and Nonbinary Persons in Clinical Trials and Tumor Registries-The Time Is Now. JAMA Oncol. 2022; 8(8):1097-1098. DOI: 10.1001/jamaoncol.2022.1638. View

Coleman E, Radix A, Bouman W, Brown G, de Vries A, Deutsch M . Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. 2022; 23(Suppl 1):S1-S259. PMC: 9553112. DOI: 10.1080/26895269.2022.2100644. View

Patel H, Bihani T . Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018; 186:1-24. DOI: 10.1016/j.pharmthera.2017.12.012. View

Brown A, Lourenco A, Niell B, Cronin B, Dibble E, DiNome M . ACR Appropriateness Criteria® Transgender Breast Cancer Screening. J Am Coll Radiol. 2021; 18(11S):S502-S515. DOI: 10.1016/j.jacr.2021.09.005. View

Kamen C, Pratt-Chapman M, Quinn G . "Sex Can Be a Great Medicine": Sexual Health in Oncology Care for Sexual and Gender Minority Cancer Patients. Curr Sex Health Rep. 2021; 12(4):320-328. PMC: 7993401. DOI: 10.1007/s11930-020-00285-1. View

Finn R, Martin M, Rugo H, Jones S, Im S, Gelmon K . Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375(20):1925-1936. DOI: 10.1056/NEJMoa1607303. View

Punjani N, Bernie H, Salter C, Flores J, Benfante N, Mulhall J . The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy. Sex Med. 2021; 9(4):100378. PMC: 8360915. DOI: 10.1016/j.esxm.2021.100378. View

Gurrala R, Kumar T, Yoo A, Mundinger G, Womac D, Lau F . The Impact of Exogenous Testosterone on Breast Cancer Risk in Transmasculine Individuals. Ann Plast Surg. 2022; 90(1):96-105. DOI: 10.1097/SAP.0000000000003321. View

Roznovjak D, Petroll A, Lakatos A, Narayan R, Cortina C . Perceptions of Transgender and Nonbinary Persons Toward Breast and Cervical Cancer Development, Screening, and Potential Impact on Gender-Affirming Hormone Therapy. JCO Oncol Pract. 2023; 19(5):e794-e800. DOI: 10.1200/OP.22.00681. View

10.

Raths F, Karimzadeh M, Ing N, Martinez A, Yang Y, Qu Y . The molecular consequences of androgen activity in the human breast. Cell Genom. 2023; 3(3):100272. PMC: 10025454. DOI: 10.1016/j.xgen.2023.100272. View

11.

de Blok C, Wiepjes C, Nota N, van Engelen K, Adank M, Dreijerink K . Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019; 365:l1652. PMC: 6515308. DOI: 10.1136/bmj.l1652. View

12.

Chan K, Jolly D, Liang J, Weinand J, Safer J . ESTROGEN LEVELS DO NOT RISE WITH TESTOSTERONE TREATMENT FOR TRANSGENDER MEN. Endocr Pract. 2018; 24(4):329-333. DOI: 10.4158/EP-2017-0203. View

13.

Fledderus A, Gout H, Ogilvie A, van Loenen D . Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening. Breast. 2020; 53:92-100. PMC: 7375644. DOI: 10.1016/j.breast.2020.06.008. View

14.

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017; 35(25):2875-2884. DOI: 10.1200/JCO.2017.73.7585. View

15.

Glaser R, Dimitrakakis C . Testosterone and breast cancer prevention. Maturitas. 2015; 82(3):291-5. DOI: 10.1016/j.maturitas.2015.06.002. View